Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Empagliflozin · 1 trial · 1 indication
change in BMI between study arms
change in glycated hemoglobin plasma concentration between study arms
| Arm | Type | Description |
|---|---|---|
| Empagliflozin 20 mg | EXPERIMENTAL | Patients receiving empagliflozin 20 mg daily |
| Empagliflozin 10 mg | ACTIVE_COMPARATOR | Patients receiving empagliflozin 10 mg daily |
| Name | Type | Description |
|---|---|---|
| Empagliflozin 20 mg | DRUG | Patients receiving empagliflozin 20 mg daily - experimental arm |
| Empagliflozin 10 mg | DRUG | Patients receiving empagliflozin 10 mg daily - control arm |
Inclusion Criteria: * diagnosis of metabolic syndrome as follows: the presence of obesity (waist circumference ≥ 88 cm in women; ≥102 cm or body mass index (BMI) ≥30 kg/m2) and two of the three following criteria: 1. high blood pressure (systolic blood pressure - in-office measurement: ≥ 130 and...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE3 | obicetrapib, ezetimibe daily |
| Veru Inc | VERU | 1 | PHASE2 | Enobosarm, Semaglutide weekly |
| Collegium Pharmaceutical, Inc. | COLL | 1 | PHASE3 | Empagliflozin |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 1 | - | Undisclosed |
| Abbott Laboratories | ABT | 1 | - | Undisclosed |
| Elevance Health, Inc. | ELV | 1 | N/A | Undisclosed |
Empagliflozin is being studied for the treatment of Metabolic Syndrome. It is an investigational small molecule in Phase 3 clinical development. The drug is being evaluated in a clinical trial enrolling 200 participants with Metabolic Syndrome.
Empagliflozin is being developed by Collegium Pharmaceutical, Inc., a company traded on the stock exchange under the ticker COLL. The company is conducting a Phase 3 clinical trial of the drug for Metabolic Syndrome.
Empagliflozin is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 3 trial is actively recruiting participants with Metabolic Syndrome.
Empagliflozin is being studied in a Phase 3 clinical trial with the identifier NCT05905965. The trial is titled 'Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment' and is recruiting 200 participants in Poland.
Yes, Empagliflozin is also known as Empagliflozin 20 mg. The clinical trial NCT05905965 evaluates the efficacy of a double dose compared to a standard dose of Empagliflozin for the treatment of Metabolic Syndrome.